Cartesian Therapeutics Inc RNAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $8.33
- Day Range
- $8.02–8.71
- 52-Week Range
- $5.60–14.56
- Bid/Ask
- $8.20 / $9.89
- Shares Outstanding
- 29.38M
- Market Cap
- $242.69M
- Volume/Avg
- 145,321 / 284,555
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 123.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
Valuation
|
Metric
|
RNAC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 123.01 |
Price/Cash Flow | — |
Price/Earnings
RNAC
Financial Strength
|
Metric
|
RNAC
|
|---|---|
Quick Ratio | 7.46 |
Current Ratio | 7.65 |
Interest Coverage | — |
Quick Ratio
RNAC
Profitability
|
Metric
|
RNAC
|
|---|---|
Return on Assets (Normalized) | −19.40% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RNAC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&fG##@ | LOCK|@Yyt | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|z^v@s<@ | LOCK|Ml#H# | $70B | |||
| argenx SE ADR
ARGX
| LOCK|yrQBYW@ | LOCK|<Y@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ZhCg$N@ | LOCK|yR^q< | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|DLy#$? | LOCK|H# | $37B | |||
| Moderna Inc
MRNA
| LOCK|<^YF>c@ | LOCK|X## | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?FN>z<#W | LOCK|&Zt$% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|S^$$>^ | LOCK|!cW | $23B | |||
| Incyte Corp
INCY
| LOCK|>J>pXt | LOCK|CJ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!PYgYC | LOCK|Kbt | $16B |
United States